Isatuximab-Irfc

Isatuximab plus pomalidomide and low-dose dexamethasone continued to show significant improvement in time to next treatment and PFS2 compared with pomalidomide and dexamethasone in relapsed or refractory multiple myeloma, according to updated results from the ICARIA-MM study.

The FDA approved isatuximab-irfc for use in combination with carfilzomib and dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma who previously received one to three prior lines of therapy.

The addition of isatuximab-irfc to carfilzomib and dexamethasone significantly prolonged PFS among patients with relapsed multiple myeloma, according to topline data released by the agent’s manufacturer.

The FDA has made several notable approvals and decisions on treatment for multiple myeloma in the past year. To highlight new and emerging therapies, Healio compiled a list of these potentially practice-changing FDA actions.